Search results
Group Leader, Stem Cell Biology at Minerva Biotechnologies. Linkedin Profile.
Mark G. Carter's 19 research works with 25 citations and 478 reads, including: Abstract 1148: 1XX mutations slow CAR T cell signaling and increase in vivo persistence.
Mark G Carter's 10 research works with 219 citations and 1,208 reads, including: Jak/Stat3 Signaling Promotes Somatic Cell Reprogramming by Epigenetic Regulation
Apr 5, 2024 · Purpose: First-in-human Phase I study for advanced MUC1* positive breast cancer with autologous T cells engineered to express either a chimeric antigen receptor, huMNC2-CAR44 or huMNC2-CAR22, which specifically bind to a cleaved form of MUC1 (MUC1*); evaluate the safety and preliminary anti-tumor activity. Methods: MUC1* (muk 1 star) is the ...
Toshio Hamatani, Mark G. Carter, Alexei A. Sharov, and Minoru S.H. Ko* Developmental Genomics and Aging Section Laboratory of Genetics Based on BrUTP incorporation studies, the minor ZGA National Institute on Aging occurs primarily in the male pronucleus (Aoki et al., National Institutes of Health 1997). This initial zygotic transcription is ...
Background: MUC1 has been one of the most important therapeutic targets for solid tumor cancers for the past 20+ years. However, no MUC1 targeted therapeutic has yet succeeded or has been granted FDA approval. Although MUC1 is overexpressed on cancer cells, it is also widely expressed on normal epithelial cells.
Group Leader, Stem Cell Biology at Minerva Biotechnologies. Show contact. Mark Carter has a long and varied work history, beginning in 1991 when they were a Clinical Laboratory Technician and Computer Systems Manager at Brigham and Women's Hospital.
